Venture Prize award brings artificial bone nearer to patient use

Venture Prize award brings artificial bone nearer to patient use

Scientists developing a material that mimics bone have won a major venture prize that takes their pioneering product a step closer to being used in patients.

The SIRAKOSS MaxSi™ Graft technology which produces purely synthetic material, with no variability in performance, has the potential to treat many thousands of patients who need spinal fusion surgery for back pain, or repairs for traumatic bone injuries.

This innovation has won SIRAKOSS - an innovative medical device company based in Edinburgh and Aberdeen and spun out of the University of Aberdeen - the £25,000 Venture Prize from The Worshipful Company of Armourers and Brasiers.

Professor Iain Gibson, a University biomaterials chemist and principal investigator of the SIRAKOSS MaxSi™ Graft technology, said: “SIRAKOSS is delighted to be recognised in this way by the Armourers and Brasiers' Company which is a prominent supporter of materials science research and commercialisation in the UK.

“Funding from the prize will help bring our unique synthetic bone material closer to market. This could help the many hundreds of thousands of people who need bone grafts or bone repairs following the type of fractures suffered in road accidents which can be difficult to heal.”

Figures for 2012 show there were 1.7 million clinical procedures using bone graft substitutes in the USA, Japan and Europe alone with approximately 90 percent of these procedures in spinal or trauma surgery.  In America alone, that same year, the market value of bone graft substitutes was $1.8 billion.

Professor Gibson and the SIRAKOSS team have spent eight years developing and refining the MaxSi™ Graft technology which has a unique chemical composition and scaffold structure for achieving bone repair and fusion.

“We are taking a different approach to the synthesis of our material which we believe will make it more successful than other artificial bone products currently available to surgeons. Our product contains no human or animal proteins which removes the risk of potential batch-to-batch variability in performance. Also, because it’s made in the lab, it could be available in endless supply.

“Currently, patients who need bone grafts will frequently have bone grafted from elsewhere in their body or from bone harvested from a cadaver. Both of these types of grafts have their issues,” explained Professor Gibson.

“You may have an elderly patient going into hospital for an operation on their back which uses bone taken from their pelvis – a process called autografting. The patient then has two operations to recover from, which is far from ideal. Also more than 30% of patients suffer long term chronic pain at the previously healthy site where the bone was harvested.

“Cadaver bone also has its problems – it has the potential for disease transmission and is of variable quality and efficacy.”

Professor Bill Bonfield, chairman of the Armourers & Brasiers Venture Prize judging panel said: “We were hugely impressed with the SIRAKOSS entry and their approach which offers surgeons a materials science alternative to pharmacological products for obtaining rapid bone repair and fusion. This has the potential to benefit thousands of people each year and it also fits well with our aim to encourage innovative scientific entrepreneurship in the UK and to provide funding, which is often difficult to source, to bring new materials science research to market.” 

Brian Butchart, CEO of SIRAKOSS added: “In a very competitive field we are delighted to have won this award which recognises the outstanding material science in the development of our synthetic bone graft and the clearly defined commercial opportunity. Receiving this recognition from the Worshipful Company of Armourers & Brasiers, which with its origins dating back to 1322, is a huge endorsement of the development efforts undertaken by the team and in particular Professor Iain Gibson and Jordan Conway.

The Prize will progress efforts in achieving regulatory approval for clinical use. The aim is to MaxSi™ Graft technology approved for use in patients in two years’ time.”

Search News

Browse by Month


  1. Jan
  2. Feb
  3. Mar
  4. Apr
  5. May
  6. Jun There are no items to show for June 2023
  7. Jul There are no items to show for July 2023
  8. Aug There are no items to show for August 2023
  9. Sep There are no items to show for September 2023
  10. Oct There are no items to show for October 2023
  11. Nov There are no items to show for November 2023
  12. Dec There are no items to show for December 2023


  1. Jan There are no items to show for January 2013
  2. Feb There are no items to show for February 2013
  3. Mar There are no items to show for March 2013
  4. Apr There are no items to show for April 2013
  5. May There are no items to show for May 2013
  6. Jun
  7. Jul
  8. Aug
  9. Sep
  10. Oct
  11. Nov
  12. Dec